istock-183060916
oonal / iStockphoto.com
20 July 2018Biotechnology

Novartis signs antibody licensing agreement with two biotechs

Novartis has signed a global licensing agreement with two biotechnology companies centring on the development of an antibody treatment for inflammatory skin conditions.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
16 July 2019   Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.

More on this story

Big Pharma
16 July 2019   Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.

More on this story

Big Pharma
16 July 2019   Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.